Ansell Benjamin J, Navab Mohamad, Hama Susan, Kamranpour Naeimeh, Fonarow Gregg, Hough Greg, Rahmani Shirin, Mottahedeh Rachel, Dave Ravi, Reddy Srinivasa T, Fogelman Alan M
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095-1679, USA.
Circulation. 2003 Dec 2;108(22):2751-6. doi: 10.1161/01.CIR.0000103624.14436.4B. Epub 2003 Nov 24.
The inflammatory/antiinflammatory properties of HDL were compared with HDL cholesterol in 2 groups of patients and in age- and sex-matched control subjects.
Group 1 consisted of 26 patients not yet taking a statin who presented with coronary heart disease (CHD) or CHD equivalents by National Cholesterol Education Program Adult Treatment Panel III criteria studied before and 6 weeks after 40 mg/d of simvastatin. Group 2 consisted of 20 patients with documented CHD and HDL cholesterol > or =84 mg/dL. The inflammatory/antiinflammatory properties of HDL were determined by the ability of the subject's HDL to alter LDL-induced monocyte chemotactic activity (MCA) in a human artery wall coculture. Induction of MCA by a control LDL was determined in the absence or presence of the subject's HDL. Values in the absence of HDL were normalized to 1.0. Values >1.0 after the addition of HDL indicated proinflammatory HDL; values <1.0 indicated antiinflammatory HDL. Group 1 values before simvastatin were LDL cholesterol, 118+/-24 mg/dL; HDL cholesterol, 57+/-13 mg/dL; triglycerides, 125+/-64 mg/dL; and high-sensitivity C-reactive protein (hs-CRP), 1.7+/-1.9 mg/L; and MCA values were 1.38+/-0.91, compared with 0.38+/-0.14 for control subjects (P=1.5x10(-5)). After simvastatin, values were LDL cholesterol, 73+/-24 mg/dL; HDL cholesterol, 61+/-14 mg/dL; triglycerides, 99+/-52 mg/dL; and hs-CRP, 1.3+/-1.3 mg/L; and MCA values were 1.08+/-0.71. In group 2, values were LDL cholesterol, 108+/-34 mg/dL; HDL cholesterol, 95+/-14 mg/dL; triglycerides, 89+/-44 mg/dL; and hs-CRP, 0.8+/-0.7 mg/L; and MCA values were 1.28+/-0.29, compared with 0.35+/-0.11 for control subjects (P=1.7x10(-14)). Similar results were obtained with the cell-free assay.
The inflammatory/antiinflammatory properties of HDL distinguished patients from control subjects better than HDL cholesterol and were improved with simvastatin.
在两组患者以及年龄和性别匹配的对照受试者中，对高密度脂蛋白（HDL）的促炎/抗炎特性与HDL胆固醇进行了比较。
第1组由26例尚未服用他汀类药物的患者组成，这些患者根据美国国家胆固醇教育计划成人治疗小组III标准，表现为冠心病（CHD）或CHD等效病症，在服用40mg/d辛伐他汀之前和之后6周进行了研究。第2组由20例确诊为CHD且HDL胆固醇≥84mg/dL的患者组成。HDL的促炎/抗炎特性通过受试者的HDL改变人动脉壁共培养中低密度脂蛋白（LDL）诱导的单核细胞趋化活性（MCA）的能力来确定。在不存在或存在受试者HDL的情况下，测定对照LDL诱导的MCA。不存在HDL时的值标准化为1.0。添加HDL后值>1.0表明HDL具有促炎作用；值<1.0表明HDL具有抗炎作用。第1组在服用辛伐他汀之前，LDL胆固醇值为118±24mg/dL；HDL胆固醇值为57±13mg/dL；甘油三酯值为125±64mg/dL；高敏C反应蛋白（hs-CRP）值为1.7±1.9mg/L；MCA值为1.38±0.（此处原文有误，应为0.91），而对照受试者的MCA值为0.38±0.14（P = 1.5×10⁻⁵）。服用辛伐他汀后，LDL胆固醇值为73±24mg/dL；HDL胆固醇值为61±14mg/dL；甘油三酯值为99±52mg/dL；hs-CRP值为1.3±1.3mg/L；MCA值为1.08±0.71。在第2组中，LDL胆固醇值为108±34mg/dL；HDL胆固醇值为95±14mg/dL；甘油三酯值为89±44mg/dL；hs-CRP值为0.8±0.7mg/L；MCA值为1.28±0.29，而对照受试者的MCA值为0.35±0.11（P = 1.7×10⁻¹⁴）。无细胞试验也得到了类似结果。（此处原文有误，应为Similar results were obtained with the cell-free assay.）
HDL的促炎/抗炎特性比HDL胆固醇能更好地区分患者与对照受试者，并且辛伐他汀可改善这些特性。
